InvestorsHub Logo
Followers 2
Posts 97
Boards Moderated 0
Alias Born 07/19/2006

Re: Aiming4 post# 14617

Friday, 12/21/2007 11:24:59 AM

Friday, December 21, 2007 11:24:59 AM

Post# of 47844
Didn't Dr Stoll say they could not do a short term study on Altzheimers? Epix did and got quite a pop in share price. Why not do a similar study using an Ampakine?

On Tuesday, Epix Pharmaceuticals (nasdaq: EPIX - news - people ) announced that its Phase II clinical trial of experimental drug PRX-03140 showed "compelling" results. Alzheimer's patients who received 150-milligram doses of PRX-03140 orally once per day for two weeks achieved an average improvement of 5.7 points on the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog). Those given 50-milligram doses once daily showed a 1.1 point improvement. Patients given a placebo averaged a .2 point decline

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News